God drug metformin anti-cancer hammer! PNAS reveals the mechanism by which metformin inhibits KRAS mutation metastatic colorectal cancer!

, June 2020 /
BiovalleyBIOON /- Metastatic colorectal cancer (mCRC) patients with either Iliticon or Oshariplatin-based chemotherapy combined with anti-EGFR (epidermal growth factor receptor) medication, the survival rate is not goodIn particular, CRC patients with KRAS mutation had limited targeted treatment options and poor overall survival rateIn many studies, metformin has been reported as a potential new anti-
tumordrug, but its therapeutic activity is different and controversialexciting, recent researchers from Sun Yat-sen University found thatdiabetes patients who treated the KRAS mutation with metformin
had a median survival time of 37.8 months longer than those treated with the combined standard system of the sugar-lowering drugIn contrast, metformin did not improve the survival of patients with mCRC combined wild KRASThe results of the study were recently published in PNAS, entitled "Metformin selectively inhibits metastatic colorectal cancer with the KRAS mutation by intra-intra-group-rich-group-through-silencing MATE1"photo source: PNAS
Interesting, researchers in experiments using primary cultured cells and patient-derived xenotransplanted cells found that metformin pre-accumulates in KRAS mutant mCRC cells, rather than wild cells, which is consistent with the significant role of metformin in KRASm mutation CRCresearchers also found that, in mechanisms, the mutated KRAS cancer protein was highly methylated and inhibited the expression of multidrug/toxin excretion protein 1 (MATE1), which can be removed fromtumorcells by raising DNA methyl metase 1 (DNMT1) overall, the results of this study provide evidence that patients with KRAS mutation mCRC benefit from metformin treatment, and targeted MATE1 may provide a strategy for improving the anti-cancer response of metformin (BioValleyBioon.com) References: Guoquan Gao et al.
Metformin selectively inhibits metastatic color cancerectal with the KRAS cone bythed yr eu geached silencing MATE1 PNAS 2020 DOI: https://doi.org/10.1073/pnas.1918845117